Skip to main content
Erschienen in:

27.05.2022 | Original Article

Transcatheter tricuspid valve-in-valve implantation with bioprosthetic balloon expandable valve

verfasst von: Ali-Mohammad Haji-Zeinali, Nasrin Etesamifard, Zohre Mohammadi, Mohammad-Mohsen Haji-Zeinali, Mohammad Sahebjam, Kiomars Abbasi

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study was conducted to evaluate the outcome of the transcatheter valve-in-valve implantation for degenerated tricuspid bioprosthetic valves with transcatheter aortic valves.

Methods

This retrospective study enrolled all consecutive patients who were considered high risk for reoperations by the heart team and who underwent transcatheter valve-in-valve implantation for degenerated tricuspid bioprosthetic valves in Tehran Heart Center, Tehran, Iran. All the procedures were performed via the transfemoral venous route under echocardiography and fluoroscopy guidance with Edwards SAPIEN transcatheter heart valves (Edwards Lifesciences, Irvine, CA).

Results

Ten patients underwent successful transcatheter valve-in-valve implantation in the tricuspid position without any major complications or need for emergency surgical interventions. The mean age was 54.1 ± 17.1 years, and 8 patients were female. The median follow-up was 19.5 months (16–32.25 mon). The mean period between the last tricuspid valve replacement and transcatheter valve-in-valve implantation was 4.9 ± 2.2 years. The bioprosthetic valves were Hancock in three patients, Mosaic in the other three patients, and Biocor, Pericarbon, Perimount, and Epic in the other patients. After the procedure, the clinical and functional status improved significantly in all the patients. The mean transvalvular gradient decreased from 6.75 ± 2.66 mm Hg to 2.85 ± 0.89 (P < 0.001), and the postoperative tricuspid regurgitation severity decreased significantly in almost all the patients. The hospitalization period after the procedure was 4.4 ± 1.7 days.

Conclusions

In high-risk patients, transcatheter valve-in-valve implantation seems to be a safe and minimally invasive alternative to reoperations for degenerated tricuspid bioprosthetic valves.
Literatur
1.
Zurück zum Zitat Asmarats L, Taramasso M, Rodés-Cabau J. Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. Nat Rev Cardiol. 2019;16(9):538–54.CrossRef Asmarats L, Taramasso M, Rodés-Cabau J. Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field. Nat Rev Cardiol. 2019;16(9):538–54.CrossRef
2.
Zurück zum Zitat Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43(3):405–9.CrossRef Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43(3):405–9.CrossRef
3.
Zurück zum Zitat Yaghoubi AR, Imani SH, Moulavipour AR, Bonow RO. A multi-center study of the pathologies of valvular heart diseases: 5 year analysis of more than 3400 patients in Iran. J Cardiovasc Thora Res. 2010;2(2):21–7. Yaghoubi AR, Imani SH, Moulavipour AR, Bonow RO. A multi-center study of the pathologies of valvular heart diseases: 5 year analysis of more than 3400 patients in Iran. J Cardiovasc Thora Res. 2010;2(2):21–7.
4.
Zurück zum Zitat Dhoble A, Zhao Y, Vejpongsa P, Loghin C, Smalling RW, Estrera A, et al. National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery. J Cardiovasc Surg (Torino). 2019;60(1):119–27. Dhoble A, Zhao Y, Vejpongsa P, Loghin C, Smalling RW, Estrera A, et al. National 10-year trends and outcomes of isolated and concomitant tricuspid valve surgery. J Cardiovasc Surg (Torino). 2019;60(1):119–27.
5.
Zurück zum Zitat Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French Nationwide Database). Am J Cardiol. 2018;122(2):323–6.CrossRef Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French Nationwide Database). Am J Cardiol. 2018;122(2):323–6.CrossRef
6.
Zurück zum Zitat Sadeghpour A, Alizadehasl A, Azizi Z, Ghavidel AA. Tricuspid regurgitation dilemma: a comparison study between surgical versus medical management of patients with tricuspid regurgitation. Multidiscip Cardio Annal. 2016;7(1): e9469. Sadeghpour A, Alizadehasl A, Azizi Z, Ghavidel AA. Tricuspid regurgitation dilemma: a comparison study between surgical versus medical management of patients with tricuspid regurgitation. Multidiscip Cardio Annal. 2016;7(1): e9469.
7.
Zurück zum Zitat Liu P, Qiao WH, Sun FQ, Ruan XL, Shirbini MA, Hu D, et al. Should a mechanical or biological prosthesis be used for a tricuspid valve replacement? A meta-analysis. J Card Surg. 2016;31(5):294–302.CrossRef Liu P, Qiao WH, Sun FQ, Ruan XL, Shirbini MA, Hu D, et al. Should a mechanical or biological prosthesis be used for a tricuspid valve replacement? A meta-analysis. J Card Surg. 2016;31(5):294–302.CrossRef
8.
Zurück zum Zitat Rizzoli G, Vendramin I, Nesseris G, Bottio T, Guglielmi C, Schiavon L, et al. Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg. 2004;77(5):1607–14.CrossRef Rizzoli G, Vendramin I, Nesseris G, Bottio T, Guglielmi C, Schiavon L, et al. Biological or mechanical prostheses in tricuspid position? A meta-analysis of intra-institutional results. Ann Thorac Surg. 2004;77(5):1607–14.CrossRef
9.
Zurück zum Zitat McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, et al. Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional surgical bioprosthetic valves: an international multicenter registry study. Circulation. 2016;133(16):1582–93.CrossRef McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, et al. Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional surgical bioprosthetic valves: an international multicenter registry study. Circulation. 2016;133(16):1582–93.CrossRef
10.
Zurück zum Zitat Poorhosseini H, Abbasi SH. The Tehran Heart Center. Eur. Heart J. 2018. Poorhosseini H, Abbasi SH. The Tehran Heart Center. Eur. Heart J. 2018.
11.
Zurück zum Zitat Haji Zeinali MA, Abbasi K, Sahebjam M, Salarifar M, Shirzad M, Yoosefpour N, et al. Initial experiences of transcatheter aortic valve implantation (TAVI) in Iran with midterm follow up. Int Cardio Res J. 2017;11(3):e11030. Haji Zeinali MA, Abbasi K, Sahebjam M, Salarifar M, Shirzad M, Yoosefpour N, et al. Initial experiences of transcatheter aortic valve implantation (TAVI) in Iran with midterm follow up. Int Cardio Res J. 2017;11(3):e11030.
12.
Zurück zum Zitat Scully HE, Armstrong CS. Tricuspid valve replacement: fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg. 1995;109(6):1035–41.CrossRef Scully HE, Armstrong CS. Tricuspid valve replacement: fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg. 1995;109(6):1035–41.CrossRef
13.
Zurück zum Zitat Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation. 2012;126(19):2335–44.CrossRef Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation. 2012;126(19):2335–44.CrossRef
14.
Zurück zum Zitat Haji Zeinali AM, Abbasi K, Sahebjam M, Yazdani S, Mortazavi H, et al. Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up). J Cardiovasc Thora Res. 2017;9(3):152–7.CrossRef Haji Zeinali AM, Abbasi K, Sahebjam M, Yazdani S, Mortazavi H, et al. Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up). J Cardiovasc Thora Res. 2017;9(3):152–7.CrossRef
15.
Zurück zum Zitat Shivaraju A, Michel J, Frangieh A, Ott I, Thilo C, Schunkert H, et al. Transcatheter aortic and mitral valve-in-valve implantation using the edwards sapien 3 heart valve. J Am Heart Assoc. 2018;7(14): e007767.CrossRef Shivaraju A, Michel J, Frangieh A, Ott I, Thilo C, Schunkert H, et al. Transcatheter aortic and mitral valve-in-valve implantation using the edwards sapien 3 heart valve. J Am Heart Assoc. 2018;7(14): e007767.CrossRef
16.
Zurück zum Zitat Godart F, Baruteau AE, Petit J, Riou J, Sassolas F, Lusson JR, et al. Transcatheter tricuspid valve implantation: a multicentre French study. Arch Cardiovasc Dis. 2014;107(11):583–91.CrossRef Godart F, Baruteau AE, Petit J, Riou J, Sassolas F, Lusson JR, et al. Transcatheter tricuspid valve implantation: a multicentre French study. Arch Cardiovasc Dis. 2014;107(11):583–91.CrossRef
17.
Zurück zum Zitat Ruparelia N, Mangieri A, Ancona M, Giannin F, Agricola E, Montorfano M, et al. Percutaneous transcatheter treatment for tricuspid bioprosthesis failure: tricuspid bioprosthesis failure treatment. Catheter Cardiovasc Interv. 2016;88(6):994–1001.CrossRef Ruparelia N, Mangieri A, Ancona M, Giannin F, Agricola E, Montorfano M, et al. Percutaneous transcatheter treatment for tricuspid bioprosthesis failure: tricuspid bioprosthesis failure treatment. Catheter Cardiovasc Interv. 2016;88(6):994–1001.CrossRef
18.
Zurück zum Zitat Viotto G, Paim L, Souza R, Aprígio J, Lacerda L, Pomerantzeff P, et al. Early outcomes of transcatheter tricuspid valve-in-valve implantation: a case series. Interact Cardiovasc Thorac Surg. 2019;29:1–5.CrossRef Viotto G, Paim L, Souza R, Aprígio J, Lacerda L, Pomerantzeff P, et al. Early outcomes of transcatheter tricuspid valve-in-valve implantation: a case series. Interact Cardiovasc Thorac Surg. 2019;29:1–5.CrossRef
19.
Zurück zum Zitat Carrier M, Hébert Y, Pellerin M, Bouchard D, Perrault L, Cartier R, et al. Tricuspid valve replacement: an analysis of 25 years of experience at a single center. Ann Thorac Surg. 2003;75(1):47–50.CrossRef Carrier M, Hébert Y, Pellerin M, Bouchard D, Perrault L, Cartier R, et al. Tricuspid valve replacement: an analysis of 25 years of experience at a single center. Ann Thorac Surg. 2003;75(1):47–50.CrossRef
Metadaten
Titel
Transcatheter tricuspid valve-in-valve implantation with bioprosthetic balloon expandable valve
verfasst von
Ali-Mohammad Haji-Zeinali
Nasrin Etesamifard
Zohre Mohammadi
Mohammad-Mohsen Haji-Zeinali
Mohammad Sahebjam
Kiomars Abbasi
Publikationsdatum
27.05.2022
Verlag
Springer Nature Singapore
Erschienen in
General Thoracic and Cardiovascular Surgery / Ausgabe 11/2022
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-022-01829-z

Weitere Artikel der Ausgabe 11/2022

General Thoracic and Cardiovascular Surgery 11/2022 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Nach größerer Op.: Wie lang in der PACU überwachen?

Ein etwa vier- bis sechsstündiges Monitoring im Aufwachraum (PACU) scheint in den meisten Fälle auszureichend zu sein, um anhand klinischer Kriterien zu entscheiden, ob es nach einer größeren Op. auf die Normalstation gehen kann.

Vertraute Bedingungen reduzieren Stress bei Operierenden

Vertrautes Personal und bekannte Räumlichkeiten tragen offenbar dazu bei, dass Operierende bei einem Eingriff weniger gestresst sind. Das zeigen Daten von vier französischen Unikliniken.

Unterarmfraktur: Tipps für ein zielgerichtetes Vorgehen

Bei Verdacht auf eine Unterarmfraktur seien 1000 Entscheidungen in 15 Minuten zu treffen, so der Kinderchirurg Dr. Stephan Rohleder auf dem Kongress für Kinder- und Jugendmedizin. Seine Tipps für ein zielgerichtetes Vorgehen erleichtern die adäquate Versorgung.

Wenige Komplikationen nach Mesh-verstärktem Bauchdeckenverschluss

Langzeitdaten der PRIMA-Studie sprechen dafür, dass das Komplikationsrisiko von Mesh-Implantaten bei bauchoperierten Personen mit hohem Risiko für Narbenhernien niedrig ist.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.